HUMA Stock Summary and Trading Ideas (Humacyte | NASDAQ:HUMA)

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Humacyte trades on the NASDAQ stock market under the symbol HUMA.

As of November 13, 2026, HUMA stock price declined to $0.56 with 4,253,246 million shares trading.

HUMA has a beta of 2.46, meaning it tends to be more sensitive to market movements. HUMA has a correlation of 0.11 to the broad based SPY ETF.

HUMA has a market cap of $155.12 million. This is considered a Micro Cap stock.

Last quarter Humacyte reported $1 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $240,000 and exceeded earnings estimates by $.02.

In the last 3 years, HUMA traded as high as $9.97 and as low as $.34.

The top ETF exchange traded funds that HUMA belongs to (by Net Assets): VTI, VXF, IBB, SCHA, VHT.

HUMA has underperformed the market in the last year with a return of -55.3%, while the SPY ETF gained +11.5%. In the last 3 month period, HUMA fell short of the market, returning -16.0%, while SPY returned -2.1%. However, in the most recent 2 weeks HUMA has outperformed the stock market by returning +18.9%, while SPY returned -1.9%.

HUMA support price is $.55 and resistance is $.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HUMA shares will trade within this expected range on the day.